Form 4: Solid Biosciences COO Granted Restricted Stock Units

David Howton, Chief Operating Officer of Solid Biosciences Inc., was granted 169,100 restricted stock units (RSUs) on January 31, 2025, vesting over four years.

Summary

• David Howton, the Chief Operating Officer of Solid Biosciences Inc., received 169,100 restricted stock units (RSUs) on January 31, 2025.
• These RSUs will vest over a four-year period, with 25% of the original number of shares vesting on each anniversary of the grant date.
• Each RSU represents a contingent right to receive one share of Solid Biosciences' common stock.
• A power of attorney was executed on February 10, 2025, granting Kimberly Cornwell the authority to handle Section 16 reporting obligations on behalf of David Howton.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management and shareholder interests. The sentiment is moderately positive due to the incentive structure.

Positives

• The grant of RSUs aligns the COO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the COO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs.

Industry Context

Grants of restricted stock units are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Executive compensation packages, including RSU grants, are common in the biotech industry.
• Companies like BioMarin, Sarepta Therapeutics, and Vertex Pharmaceuticals also utilize equity-based compensation to incentivize their executives.
• The vesting schedule of four years is a typical timeframe for RSU grants in this sector.

Stakeholder Impact

• Shareholders: The RSU grant aligns the COO's interests with those of shareholders, incentivizing long-term value creation.
• Employees: The grant may have a positive impact on employee morale as it demonstrates the company's commitment to its leadership.

Key Dates

Keywords

Solid Biosciences, Restricted Stock Units, RSUs, Form 4, David Howton, COO, Beneficial Ownership, Section 16, Kimberly Cornwell, Power of Attorney